High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): A 3-year interim report

JAMA Neurology

Volumn 72, Issue 2, 2015, Pages 159-169

  Nash, Richard A ^a   Hutton, George J ^b   Racke, Michael K ^c   Popat, Uday ^d   Devine, Steven M ^e   Griffith, Linda M ^f   Muraro, Paolo A ^g   Openshaw, Harry ^h   Sayre, Peter H ^i,j   Stüve, Olaf ^k,l,m   Arnold, Douglas L ⁿ   Spychala, Meagan E ^o,p   McConville, Kaitlyn C ^p   Harris, Kristina M ^j   Phippard, Deborah ^j   Georges, George E ^q,r   Wundes, Annette ^r   Kraft, George H ^s   Bowen, James D ^t  

^a Rocky Mountain Blood and Marrow Transplant Program   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Oncology and Bone Marrow Transplantation   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Immune Tolerance Network   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^m JAMA   (United States)

ⁿ MCGILL UNIVERSITY   (Canada)

^o NeuroRx   (Canada)

^p RHO INC   (United States)

^q USA   (United States)

^r UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^s UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^t SWEDISH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARMUSTINE; CD34 ANTIGEN; CYTARABINE; ETOPOSIDE; FILGRASTIM; MELPHALAN; PREDNISONE; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIOVENOUS MALFORMATION; ARTICLE; ASEPTIC MENINGITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; ATRIOVENTRICULAR BLOCK; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACKACHE; BACTERIAL INFECTION; BLURRED VISION; CARDIOMYOPATHY; CD34 SELECTION; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COGNITIVE DEFECT; CYTOPENIA; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; ENGRAFTMENT SYNDROME; EPISTAXIS; EVENT FREE SURVIVAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; FOLLOW UP; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HEADACHE; HEART ATRIUM THROMBOSIS; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPESTHESIA; HYPOKALEMIA; HYPONATREMIA; IMMUNOGLOBULIN DEFICIENCY; LIMB PAIN; LUNG EMBOLISM; MALE; MANIA; MORTALITY; MOTOR DYSFUNCTION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NECK PAIN; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; RELAPSE; REMISSION; RESPIRATORY ARREST; RESPIRATORY FAILURE; SENSORY DYSFUNCTION; SIDE EFFECT; STEM CELL MOBILIZATION; SUICIDE ATTEMPT; THORAX PAIN; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; ADVERSE EFFECTS; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROCEDURES;

ADULT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84923015120     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.3780     Document Type: Article

References (34)

1. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(pt 5):1175-1189.
2. Reingold SC, Steiner JP, Polman CH, et al. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology. 2009;73(7):552-559.
3. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858-1865.
4. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260.
5. Coles AJ, Twyman CL, Arnold DL, et al; CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839.
6. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008;7(7):626-636.
7. Nash RA. Hematopoietic cell transplantation for autoimmune diseases. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopoietic Cell Transplantation. 4th ed. Oxford, England: Wiley-Blackwell; 2009:1014-1029.
8. Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997;20(8):631-638.
9. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102(7):2364-2372.
10. Saccardi R, Kozak T, Bocelli-Tyndall C, et al; Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler. 2006;12(6):814-823.
11. Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology. 2011;76 (12):1066-1070.
12. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
14. + cells from blood stem cell components using the Baxter Isolex system. Bone Marrow Transplant. 1998;21(12):1253-1262.
15. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5):871-882.
16. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124(pt 5):962-973.
17. Caramanos Z, Narayanan S, Arnold DL. SIENA-based estimates of brain-volume change in a clinical-trial setting: use of an incremental-change-summation approach to evaluate different imputation methods used to estimate missing data. Mult Scler J. 2010;16(suppl 10):S109-S110.
18. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL; Canadian MS BMT Study Group. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology. 2006;66(12):1935-1937.
19. Filippi M, Rocca MA, Arnold DL, et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol. 2006;13(4):313-325.
20. National Cancer Institute. Common terminology criteria for adverse events, version 3.0, March 31, 2003. Cancer Therapy Evaluation Program. Published August 9, 2006. http://ctep.cancer.gov. Accessed November 18, 2014.
21. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
22. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Multiple Sclerosis Functional Composite (MSFC) administration and scoring manual. National Multiple Sclerosis Society. http://main.nationalmssociety.org/docs/HOM/MSFC-Manual-and-Forms.pdf. Revised October 2001. Accessed March 8, 2013.
23. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41(8):1193-1196.
24. Turner AP, Williams RM, Bowen JD, Kivlahan DR, Haselkorn JK. Suicidal ideation in multiple sclerosis. Arch Phys Med Rehabil. 2006;87(8): 1073-1078.
25. Daikeler T, Labopin M, Di Gioia M, et al; EBMT Autoimmune Disease Working Party. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011;118(6):1693-1698.
26. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8 (3):244-253.
27. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805-816.
28. Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124(3):1168-1172.
29. Mancardi GL, Sormani MP, Di Gioia M, et al; Italian BMT Study Group. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler. 2012;18(6):835-842.
30. Darlington PJ, Touil T, Doucet J-S, et al; Canadian MS/BMT Study Group. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73(3):341-354.
31. Berard JA, Bowman M, Atkins HL, Freedman MS, Walker LA. Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. J Neurol Sci. 2014;336(1-2):132-137.
32. Saccardi R, Freedman MS, Sormani MP, et al; European Blood and Marrow Transplantation Group; Center for International Blood and Marrow Research; HSCT in MS International Study Group. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012;18(6):825-834.
33. Pfender N, Saccardi R, Martin R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr Treat Options Neurol. 2013;15(3):270-280.
34. Atkins HL, Freedman MS. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics. 2013;10(1):68-76.